Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Axsome Therapeutics, Inc. (AXSM)
|
Add to portfolio |
|
|
|
| Price: |
$51.71
| | Metrics |
| OS: |
47.2
|
M
| |
|
|
| Market cap: |
$2.44
|
B
| |
-1807
|
% ROIC
|
|
Net cash:
|
$437
|
M
| |
$9.26
|
per share
|
|
EV:
|
$2
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($232)
|
M
| |
|
|
| EPS |
($4.02)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-05-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 58.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 58.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 0.0% | | | | | | | |
| Selling, general and administrative | 66.6 | 124.7 | 99.1 | 67.2 | | | | |
| Research and development | | | | | 23.5 | 20.0 | 21.2 | 6.8 |
| General and administrative | | | | | 9.4 | 7.2 | 6.3 | 2.4 |
| EBIT | -124.7 | 0.0 | 0.0 | 0.0 | -32.8 | -27.2 | -27.5 | -9.4 |
| EBIT margin | -214.8% | | | | | | | |
| Pre-tax income | -130.4 | -130.4 | -102.9 | -68.3 | -31.0 | -28.9 | -27.2 | -12.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -130.4 | -130.4 | -102.9 | -68.3 | -31.0 | -28.9 | -27.2 | -12.2 |
| Net margin | -224.6% | | | | | | | |
| |
| Diluted EPS | ($3.47) | ($3.47) | ($2.77) | ($2.01) | ($1.15) | ($1.27) | ($1.42) | ($1.02) |
| Shares outstanding (diluted) | 37.6 | 37.6 | 37.2 | 34.0 | 26.9 | 22.8 | 19.2 | 11.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|